The SMA Trust: The role of a disease-focused research charity in developing treatments for SMA

Gene Therapy

Volumn 24, Issue 9, 2017, Pages 544-546

  Christie Brown, V ^a   Mitchell, J ^a   Talbot, K ^a  

^a SMA Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SURVIVAL MOTOR NEURON PROTEIN 2;

CLINICAL RESEARCH; GENE THERAPY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN SPLICING; REVIEW; SPINAL MUSCULAR ATROPHY; SYSTEMIC DISEASE; ECONOMICS; FINANCIAL MANAGEMENT; MEDICAL RESEARCH; ORGANIZATION AND MANAGEMENT; PROCEDURES; SOCIAL WELFARE;

BIOMEDICAL RESEARCH; CHARITIES; GENETIC THERAPY; HUMANS; MUSCULAR ATROPHY, SPINAL; RESEARCH SUPPORT AS TOPIC;

EID: 85032501264     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2017.47     Document Type: Review

References (29)

1. Talbot K, Tizzano EF. The clinical landscape for SMA in a new therapeutic era. Gene Therapy 2017; 24, 529-533.
2. Lefebvre S, Bürglen L, Reboullet S, Clermont O, Burlet P, Viollet L et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995; 80: 155-165.
3. Burghes AH, Beattie CE. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat Rev Neurosci 2009; 10: 597-609.
4. Monani UR, Lorson CL, Parsons DW, Prior TW, Androphy EJ, Burghes AH et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet 1999; 8: 1177-1183.
5. Feldkotter M, Feldkötter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 2002; 70: 358-368.
6. Riessland M, Kaczmarek A, Schneider S, Swoboda KJ, Löhr H, Bradler C et al. Neurocalcin delta suppression protects against spinal muscular atrophy in humans and across species by restoring impaired endocytosis. Am J Hum Genet 2017; 100: 297-315.
7. Shababi M, Glascock J, Lorson CL. Combination of SMN trans-splicing and a neurotrophic factor increases the life span and body mass in a severe model of spinal muscular atrophy. Hum Gene Ther 2011; 22: 135-144.
8. Hosseinibarkooie S, Peters M, Torres-Benito L, Rastetter RH, Hupperich K, Hoffmann A et al. The power of human protective modifiers: PLS3 and CORO1C unravel impaired endocytosis in spinal muscular atrophy and rescue SMA phenotype. Am J Hum Genet 2016; 99: 647-665.
9. Hammond SM, Hazell G, Shabanpoor F, Saleh AF, Bowerman M, Sleigh JN et al. Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. Proc Natl Acad Sci USA 2016; 113: 10962-10967.
10. Dominguez E, Marais T, Chatauret N, Benkhelifa-Ziyyat S, Duque S, Ravassard P et al. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet 2011; 20: 681-693.
11. Benkhelifa-Ziyyat S, Besse A, Roda M, Duque S, Astord S, Carcenac R et al. Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice. Mol Ther 2013; 21: 282-290.
12. Tanguy Y, Biferi MG, Besse A, Astord S, Cohen-Tannoudji M, Marais T et al. Systemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice. Front Mol Neurosci 2015; 8: 36.
13. Bucher T, Dubreil L, Colle MA, Maquigneau M, Deniaud J, Ledevin M et al. Intracisternal delivery of AAV9 results in oligodendrocyte and motor neuron transduction in the whole central nervous system of cats. Gene Ther 2014; 21: 522-528.
14. Duque SI, Arnold WD, Odermatt P, Li X, Porensky PN, Schmelzer L et al. A large animal model of spinal muscular atrophy and correction of phenotype. Ann Neurol 2015; 77: 399-414.
15. Valori CF, Ning K, Wyles M, Mead RJ, Grierson AJ, Shaw PJ et al. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med 2010; 2: 35ra42.
16. Lutz CM, Kariya S, Patruni S, Osborne MA, Liu D, Henderson CE et al. Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy. J Clin Invest 2011; 121: 3029-3041.
17. Kariya S, Obis T, Garone C, Akay T, Sera F, Iwata S et al. Requirement of enhanced survival motoneuron protein imposed during neuromuscular junction maturation. J Clin Invest 2014; 124: 785-800.
18. Ning K, Drepper C, Valori CF, Ahsan M, Wyles M, Higginbottom A et al. PTEN depletion rescues axonal growth defect and improves survival in SMN-deficient motor neurons. Hum Mol Genet 2010; 19: 3159-3168.
19. Powis RA, Karyka E, Boyd P, Côme J, Jones RA, Zheng Y et al. Systemic restoration of UBA1 ameliorates disease in spinal muscular atrophy. JCI Insight 2016; 1: 1-16.
20. Wishart TM, Mutsaers CA, Riessland M, Reimer MM, Hunter G, Hannam ML et al. Dysregulation of ubiquitin homeostasis and beta-catenin signaling promote spinal muscular atrophy. J Clin Invest 2014; 124: 1821-1834.
21. Sleigh JN, Gillingwater TH, Talbot K. The contribution of mouse models to understanding the pathogenesis of spinal muscular atrophy. Dis Model Mech 2011; 4: 457-467.
22. Hamilton G, Gillingwater TH. Spinal muscular atrophy: going beyond the motor neuron. Trends Mol Med 2013; 19: 40-50.
23. Wirth B, Barkats M, Martinat C, Sendtner M, Gillingwater TH. Moving towards treatments for spinal muscular atrophy: hopes and limits. Expert Opin Emerg Drugs 2015; 20: 353-356.
24. Thomson AK, Somers E, Powis RA, Shorrock HK, Murphy K, Swoboda KJ et al. Survival of motor neurone protein is required for normal postnatal development of the spleen. J Anat 2017; 230: 337-346.
25. Szunyogova E, Zhou H, Maxwell GK, Powis RA, Francesco M, Gillingwater TH et al. Survival Motor Neuron (SMN) protein is required for normal mouse liver development. Sci Rep 2016; 6: 34635.
26. Sintusek P, Catapano F, Angkathunkayul N, Marrosu E, Parson SH, Morgan JE et al. Histopathological defects in intestine in severe spinal muscular atrophy mice are improved by systemic antisense oligonucleotide treatment. PLoS ONE 2016; 11: e0155032.
27. Somers E, Lees RD, Hoban K, Sleigh JN, Zhou H, Muntoni F et al. Vascular defects and spinal cord hypoxia in spinal muscular atrophy. Ann Neurol 2016; 79: 217-230.
28. Sleigh JN, Barreiro-Iglesias A, Oliver PL, Biba A, Becker T, Davies KE et al. Chondrolectin affects cell survival and neuronal outgrowth in in vitro and in vivo models of spinal muscular atrophy. Hum Mol Genet 2014; 23: 855-869.
29. Little D, Valori CF, Mutsaers CA, Bennett EJ, Wyles M, Sharrack B et al. PTEN depletion decreases disease severity and modestly prolongs survival in a mouse model of spinal muscular atrophy. Mol Ther 2015; 23: 270-277.